Introduction
Standard treatments with alkylating agents, fludarabine and even monoclonal antibodies do not cure chronic lymphocytic leukemia (CLL), in part because they leave residual tumor cells behind to cause disease recurrence and eventual death of the patient. 1 Novel agents, and strategies to improve the efficacy of existing ones, are needed to improve the outcome of CLL patients.
CLL cells can potentially be eliminated by strong anti-tumor T-cell responses. 1 However, even in the presence of high numbers of tumor-reactive cytotoxic T cells (CTLs), tumor cells often survive because of their inherently weak immunogenicity. 2 Accordingly, T-cell-mediated immunotherapies might be more effective with adjuvant strategies to increase the antigenpresenting capabilities of CLL cells and their susceptibility to lysis by CTLs. 3 Recent studies suggest that agonists of selected Toll-like receptors (TLRs) may satisfy this need for adjuvants to improve the efficacy of CLL chemotherapy and immunotherapy. Advances in the understanding of TLRs, and the identification of small-molecule TLR-agonists, have set the stage for potential exploitation in new treatment strategies for CLL. In this article, we review the biology of TLRs, particularly TLR-7 and TLR-9, which are expressed on CLL cells in a manner that makes them suitable for 'targeted therapy'. We present the evidence that supports a role for TLR agonists in the management of CLL and discuss ongoing clinical trials of these agents.
Overview of TLRs
The TLR family was first identified on the basis of homology to Drosophila Toll, which mediates anti-microbial defenses in these insects. 4 There are 10 known TLRs in humans, which are preferentially expressed on cells of the innate immune system including monocytes, macrophages, myeloid cells such as neutrophils and eosinophils, natural killer cells and dendritic cells (DCs). 5 In addition, some TLRs are found on endothelial cells, 6 platelets, 7 epithelial cells, 8 B lymphocytes 9 and T-cell subsets, including regulatory T cells (Tregs). 10 TLR ligands include pathogen-associated molecular patterns (PAMPs) on infectious microorganisms, endogenous molecules and synthetic agonists. 5 For example, TLR-2 forms heterodimers with TLR-1 and TLR-6 that recognize bacterial lipoproteins and lipoteichoic acid. TLR-4 recognizes endotoxin or lipopolysaccharide (LPS) on Gram-negative bacteria, and TLR-5 recognizes bacterial flagellin. The ligand for TLR- 10 has not yet been identified, although it seems likely to be of bacterial origin because of the genetic relationship of TLR-10 to TLR-1 and TLR-6.
5 TLR-9 recognizes unmethylated cytosine-phosphate-guanosine (CpG) motifs associated with bacterial DNA that can be mimicked by synthetic oligonucleotides. Some TLRs recognize viral PAMPs.
11 TLR-3 binds double-stranded viral RNA (dsRNA), and there is some evidence that TLR-8 can be activated by single-stranded RNA. 12 The natural ligand for human TLR-7 has not been elucidated yet. However, a number of synthetic compounds, including imidazoquinolines 13 and oxidized guanosines, 14 are both TLR-7 and TLR-8 agonists. Although the details vary somewhat for specific TLRs, signaling through TLRs generally culminates in the production of pro-inflammatory cytokines, including type I interferons (IFNs), chemokines and costimulatory molecules that activate adaptive T-cell-mediated immunity. 15 In most experimental models, TLR agonists drive adaptive immunity toward a predominantly type 1 (Th1) response, which is thought to be required for effective tumor clearance. 3 Some TLR agonists also have anti-angiogenic properties by causing the production of angiogenesis inhibitors, such as type I IFNs. 16 As CLL cells can be susceptible to T-cell-mediated immune responses directed against CLL antigens, 17, 18 and angiogenesis is associated with CLL progression, [19] [20] [21] some TLR agonists might be expected to have therapeutic efficacy in CLL through indirect effects on anti-tumor immunity and angiogenesis. However, B cells exhibit a unique profile of expression of TLRs, 22 some of which have a highly restricted tissue distribution. Accordingly, CLL cells (which are thought to be transformed CD5 þ B cells 17 ) may be specifically affected by some TLR ligands, which may be exploited for the treatment of CLL patients.
TLR expression and signaling in normal B cells
Expression of TLR mRNA in B cells appears to be developmentally regulated. 23 Naive (CD19 þ CD27 À CD38 À IgD þ ) B cells express only low levels of TLR-1, TLR-2, TLR-6, TLR-7, TLR-9 and TLR-10. Activated B cells, including germinal center
cells, express high levels of TLR-6, TLR-7, TLR-9 and TLR-10 along with low levels of TLR-1 and TLR-2 message. 23 However, circulating and tonsillar B cells have been found to make only TLR-1, TLR-2, TLR-7, TLR-9 and TLR-10 proteins, whose expression was not developmentally regulated, suggesting that TLRs are controlled by post-transcriptional mechanisms in human B cells. 24, 25 It is notable that, unlike murine B cells, human B cells do not express TLR-4 or respond to LPS.
Expression of TLR-10 seems relatively specific to B cells whereas TLR-1 and TLR-2 dimers are generally expressed on leucocyte subsets and non-immune cells, along with B cells. 26, 27 TLR-7 and TLR-9 are expressed by plasmacytoid DCs (pDCs) in addition to B cells. 28 As synthetic agonists are known (see above), the restricted distribution of these receptors makes them especially suitable for therapeutic modulation in B-cell diseases. Unlike most other TLRs (which are cell-surface molecules), TLR-7 and TLR-9 are found in endosomes. 29 However, TLR-9 can move to the cell surface in response to activating signals. 24 Binding of TLR-7 and TLR-9 to their respective agonists, activates two major signaling pathways in normal B cells (Figure 1 ). One pathway involves the MyD88-independent production of type I IFNs. 15 However, the major pathway involves the MyD88-dependent activation of nuclear factorkappaB (NF-kB), Jun kinase (JNK) and p38 by sequential activation of intermediates, such as tumor necrosis factor (TNF) receptor-associated factor (TRAF)-6, interleukin (IL)-1 receptor-associated kinase (IRAK)-1 and TGFb-activated kinase 1 (TAK1), culminating in the production of pro-inflammatory cytokines, such as TNF-a, IL-12 and IL-1, and costimulatory molecules such as CD40, CD80 and CD86. MyD88 also binds phosphatidylinositol 3-kinase (PI3K) directly, leading to the activation of v-Akt murine thymoma viral oncogene homolog (Akt) by TLRs. 30 
TLR expression in CLL cells
The spectrum of TLR expression by CLL cells has not been studied as extensively as for normal B cells. It has been established by several groups that TLR-7 and TLR-9 mRNA are invariably expressed by CLL cells. [31] [32] [33] 39 Expression of TLR-9 protein (but not TLR-7) has also been reported. 31 The relationship of TLR-7 and TLR-9 expression to the biological markers of CLL (akin to the developmental regulation of TLR expression described for normal B cells) is not clear. For example, CLL cells with somatic hypermutation at the immunoglobulin locus, and low expression of ZAP-70 and CD38, often have low-risk cytogenetic abnormalities, such as 13q14 deletions. 55 Cells with 13qÀ abnormalities were reported to express higher levels of TLR-9 mRNA 56 but this observation was not confirmed at the protein level. 31 In addition, TLR expression is subject to control by cytokines, such as type 1 IFNs. 34 Published data indicate that CLL cells do not normally express TLR8 mRNA, 35 or TLR-3 and TLR-4 proteins (as measured by responses to dsRNA or LPS, respectively 32 ). However, gene array and proteomic studies are needed to document fully the expression of TLRs, other than TLR-7 and TLR-9 (along with additional components of TLR-signaling pathways) by CLL cells.
Responses of CLL cells to TLR-7 and TLR-9 agonists
Most of the reported laboratory studies of TLR-activation in CLL cells, as well as the early clinical trials, involve TLR-7 and TLR-9 agonists. Since TLR-7 and TLR-9-employ the same signaling pathways 36 ( Figure 1 ), their agonists would be expected to affect CLL cells in a similar fashion and, for the most part, this is true. For example, TLR-9-agonist CpG oligonucleotides cause CLL cells to proliferate in vitro and increase their expression of MHC class I and costimulatory molecules, including members of the B7-family (CD80 and CD86), adhesion molecules (CD54 and CD58) and TNF-receptor family (CD40). 37 The increased expression of these molecules suggests that CLL cells treated with CpG oligonucleotides become more immunogenic, or able to support functional type 1 immune responses. Consistent with this, Decker et al. 37 showed that CpG-treated cells could stimulate the proliferation of T cells in allogeneic mixed lymphocyte responses (MLRs). In addition, these authors found that some CLL patient samples expressed TNF-a and IL-6 after stimulation with CpG oligonucleotides. Similar observations regarding the effect of CpG oligonucleotides on costimulatory molecule expression have been made by Jahrsdorfer et al. [38] [39] [40] Qualitatively similar findings have been made with imidazoquinolines, which are agonists of TLR-7. 32, 35, 41 Consistent with signaling through TLR-7, the imidazoquinoline, S28690, activated the NF-kB, JNK and p38 pathways, which were blocked by the IRAK1 inhibitor, AG126, and the endosomal inhibitors, chloroquine and bafilomycin.
32 S28690 invariably increased the expression of the costimulatory molecules that were reported to be increased by CpG oligonucleotides, and also stimulated TNF-a and IL-6 production. However, the magnitude of TNF-a and IL-6 production appears to be almost 10-fold higher after TLR-7 activation, compared with CpG oligonucleotides. 32, 37 Whether this finding reflects true differences between TLR-9 and TLR-7 signaling in CLL cells, properties of imidazoquinolines and CpG oligonucleotides that are independent of their activity on TLRs, variability in the patient samples studied, or the use of serum-free culture conditions in the TLR-7 studies is not clear.
TLR-7-activated CLL cells generally also made IL-8, IL-10, IP-10 (CXCL7) and lymphotoxin-a, and a few patient samples made IFN-g and IL-1b. 32 Unlike macrophages or pDCs, TLR-7-activated CLL cells generally made very little type I IFN or IL-12. As TLR-7-receptor signaling has been reported to cause IFN-b gene transcription by activating its transcription factor, IFNresponse factor (IRF)-5 ( Figure 1) , 42 the lack of IFN-a production by CLL cells in response to imidazoquinolines may be due to the B-cell origin of CLL cells or defective IFN-responses that have been described previously in cancer cells. 43 The magnitude of cytokine production by TLR-7-or TLR-9-activated CLL cells appears to be at least twofold less than by similarly activated normal B cells, 32, 37 even in the presence of costimuli (phorbol esters in the case of TLR-7 agonists 32 and CD40-ligand (CD40L) in the case of TLR-9 agonists 37 ). TNF-a is an exception to this statement for reasons that are not clear.
TLR-7-activated CLL cells did not proliferate strongly, 32, 41 unlike CLL cells activated with CpG oligonucleotides. 37 Another difference is the ability to stimulate T-cell proliferation in MLRs. 32, 37 In contrast to TLR-9-activated cells, TLR-7-activated CLL cells remained weak stimulators, and required additional signals from IL-2-receptor (IL-2R)-b chain binding cytokines, such as IL-2 and IL-15, 44 and protein kinase C (PKC) agonists, such as Bryostatin and Bryostatin analogs, 41, 45 to cause T cells to proliferate in vitro.
Taken together, the results suggest that TLR-7 and TLR-9 agonists affect CLL cells in qualitatively similar ways, but the cells treated only with CpG oligonucleotides may be more immunogenic than CLL cells treated only with imidazoquinolines.
Context-dependent signaling through TLRs in CLL cells
All studies reporting functional effects of TLR agonists on CLL cells have used non-proliferating circulating tumor cells. ↑IL10 ↓IL10 Figure 1 Signal transduction through TLR-7 and TLR-9 in CLL cells. Endosomally located TLR-7 and TLR-9 associate with the adaptor protein, MyD88, upon activation by their ligands. The TLR-MyD88 complex recruits IRAK1, which in turn binds TRAF6. IRAK1 and TRAF6 then dissociate from the TLR-receptor complex and interact with a mitogen-activated protein kinase Kinase Kinase, TAK1. TRAF6 activates TAK1 via ubiquination that, in turn, releases NF-kB transcription factors from inhibitor of NF-kB, and also phosphorylates and activates JNK and p38. Activated JNK and p38 then translocate to the nucleus where they phosphorylate and activate components of activator protein-1, including c-Jun and c-Fos, which (together with NF-kB family members) mediate transcription of genes such as TNF-a, IL-6 and FAS. 79 MyD88 also binds PI3K leading to the activation of Akt. 30 TLR-7 and TLR-9 control type I IFN production by some cells by activating the transcription factor, IRF-5. However, this pathway is relatively weak in CLL cells. TLR-activated CLL cells are sensitized to killing by CTLs and some chemotherapeutic agents in vitro. 32, 56, 64 The STAT3 pathway is activated in TLR-7-activated CLL cells by autocrine production of cytokines, such as IL-6. In the presence of PKC agonists, STAT3 activation is blocked, IL-10 production is inhibited, and the cells become more immunogenic, particularly when co-activated by IL-2. 41 Although these cells are easily obtained, targeting them contributes little to long-term clinical remissions. No formal studies have been reported of the effects of TLR agonists on CLL cells in the proliferation centers in bone marrow and lymphoid organs that maintain the pool of circulating cells, and are responsible for disease progression after conventional treatment. 33 There is reason to suspect that CLL cells in different phases of the cell cycle may respond differently to TLR activation. For example, cyclin E (expressed by cells in late G 1 ) can inhibit NFkB-mediated gene transcription, 46 an important downstream effector of TLR-7 and TLR-9 ( Figure 1) . A comparison of TLR signaling in circulating CLL cells with cells from the bone marrow would help to determine whether TLR agonists affect the proliferative compartment in a similar fashion as the circulating CLL compartment.
Different interactions with the microenvironments of the lymphoid organs and blood may account for altered responses to TLR agonists in the proliferative and circulating CLL compartments. 47 TLR signaling in CLL cells has been shown to be affected by such interactions. For example, concomitant signaling through the TNF-family member, CD40, resulted in increased proliferation of the CLL cells, and increased expression of CD58, CD80 and CD86. CLL cells activated with both CD40L and CpG oligonucleotides made more TNF-a than similarly treated normal B cells, as described above, 37 but did not acquire an enhanced ability to stimulate T-cell proliferation.
CLL cells treated with both CpG oligonucleotides and IL-2 proliferated strongly, as a result of increased expression of cyclins D2 and D3, and loss of the cell-cycle inhibitor, p27. 48, 49 In fact, Decker et al. 37 have proposed that CLL cells, treated with IL-2 and CpG oligonucleotides, may be used to model the proliferative CLL compartment in vitro. Similar effects are observed when CLL cells are treated with both IL-2 and TLR-7 agonists, including imidazoquinolines 41 and the oxidized guanosine analog, loxoribine.
50 TLR-7 agonists increased expression of the high-affinity IL-2R component, CD25, on CLL cells and the resultant increased IL-2R signaling presumably accounts for the proliferative synergy. 41 CLL cells treated with both IL-2 and TLR-7 agonists markedly increased their expression of CD80, but failed to acquire strong T-cell stimulatory ability, which was associated with strong activation of the immunosuppressive transcription factor, STAT3, 51 and enhanced production of the immunosuppressive cytokine, IL-10. 41 The production of IL-10 suggests that CLL cells treated with both IL-2 and TLR-7 agonists may behave like Tregs. 52 If CLL cells activated through IL-2Rs and TLR-7 actually represent the proliferative CLL-B cell compartment, 48 then both the immunodeficiency associated with CLL, 53 and the modest effectiveness of current immunotherapeutic approaches to CLL, 54 may be associated with the intrinsic immunosuppressive activity of this compartment.
In contrast, treatment of TLR-7-activated CLL cells with PKC agonists upregulates expression of the DC marker, CD83, along with CD80, CD86 and CD54, and inhibits STAT3 activation, possibly by blocking autocrine signaling through IL-6 and IL-10 receptors. 32 However, CLL cells treated only with TLR-7 and PKC agonists remain relatively weak stimulators of T-cell proliferation. Remarkably, PKC agonists cause CLL cells that have been costimulated with IL-2 and TLR-7 agonists to exit the cell cycle, switch off IL-10 production, and acquire both the phenotypic and functional characteristics of highly immunostimulatory DCs. 41 These interactions of immunologically relevant molecules with TLR agonists may suggest novel immunotherapeutic strategies for CLL, as described below. Studies of the effects of TLR agonists in combination with other molecules in the CLL microenvironment, such as integrins or extracellular matrix molecules, 47 have not yet been reported, but are necessary to further delineate different effects of TLR agonists on the circulating and proliferating CLL compartments.
Effect of biological markers of CLL progression on responses to TLR agonists
Despite consistent changes in cytokine production and costimulatory molecule expression, the magnitudes of the responses of individual CLL samples to stimulation through TLRs are strikingly heterogeneous. This observation may reflect the fact that CLL, itself, is a heterogeneous disease on the basis of clinical presentation and intrinsic biological properties. 55 Some of the inter-patient variability in responsiveness to TLR agonists is associated with underlying cytogenetic abnormalities. For example, greater proliferation after stimulation with CpG oligonucleotides was observed in samples with trisomy 12, 17pÀ and 11qÀ abnormalities, which are associated with drug resistance and an adverse outcome. 56 The magnitude of changes in the expression of some costimulatory molecules in response to imidazoquinolines was found to be directly proportional to the expression of CD38, which is also associated with more aggressive disease. 32 Production of a number of cytokines in response to imidazoquinolines was also greater in patients with advanced-stage disease, whose tumor cells are known to have a greater proportion of adverse cytogenetic abnormalities and higher CD38 expression. 41 The apparently enhanced responses of more aggressive CLL cells to TLR stimulation are not yet fully explained. They do not appear to be caused simply by differences in expression of the respective TLRs. 31 However, a recent study has suggested that greater proliferation of CLL cells with unmutated immunoglobulin V H genes is caused by enhanced CpG-mediated activation of Akt in these cells. 31 Although the direct effects of cytogenetic abnormalities on signaling by TLR-7 and TLR-9 have not been studied in detail, observations of enhanced responses of cells with 17p-and 11q-abnormalities may suggest roles for p53 and the DNA repair gene, ataxia telangiectasia mutated, respectively, in TLR-7 and TLR-9 signaling. A role for p53 would be consistent with murine studies showing that p53 suppresses endotoxin responses (presumably through TLR-4) by inhibiting the transcription of NFkB-dependent promoters, which are also activated by TLR-7 and TLR-9 ( Figure 1 ). 57 
Promotion of CLL cell death by TLR agonists
An observation that has been made repeatedly is that CLL cells exposed to TLR agonists become more sensitive to a variety of cytotoxic agents. CpG oligonucleotides have been reported to kill CLL cells directly (especially cells with 13qÀ abnormalities) after causing an initial burst of proliferation. 56 However, the effects are observed only after several days of culture and the mechanism is not entirely clear. A number of death receptors, including DR5 and FAS, are increased on CpG-activated CLL cells, but cell death is not blocked by the respective antagonists. 56 Given that other TLR agonists, such as endotoxin, stimulate mitochondrial biogenesis, 58 it is possible that mitochondrial death pathways 59 are activated by CpG oligonucleotides.
More compelling observations, from the standpoint of clinical application, are that TLR-9 agonists act synergistically with a number of existing cancer treatment modalities. The ability of CpG oligonucleotides to increase the expression of a number of surface molecules on CLL cells suggests that they may augment the efficacy of drugs that target these molecules. For example, killing of CLL cells by IL-2R toxins was markedly improved by pre-treating the cells with CpG oligonucleotides, in part because of increased CD25 expression which caused greater uptake of the toxins. 60 Similar considerations probably apply to other molecules, whose expression is increased by TLR-9 agonists, such as CD20, which is targeted by the widely used antibody, rituximab. 61 The ability of CpG oligonucleotides to activate monocytes may also potentiate antibody therapies by increasing antibody-directed cellular cytotoxicity. 62 In a pre-clinical study, the efficacy of g-irradiation was increased markedly by concomitant treatment of tumor-bearing mice with CpG oligonucleotides. 63 In this case, the TLR-9 agonists appeared to act mainly by activating anti-tumor immunity, rather than through direct effects on the tumor cells.
Direct killing of CLL cells by TLR-7 agonists has not been studied formally but is not a striking effect in vitro. However, acquisition of sensitivity to cytotoxic agents appears also to be a major phenotype of TLR-7-activated CLL cells. Long before it was shown to be a TLR-7 agonist, 14 loxoribine was found to cause CLL cells to enter the cell cycle and exhibit enhanced sensitivity to cycle-active cytotoxic drugs, such as doxorubicin and etoposide. 64 Similar observations of enhanced sensitivity to fludarabine by loxoribine were made by other authors. 65, 66 As with CpG oligonucleotides and imidazoquinolines, costimulation with IL-2 and loxoribine resulted in proliferative synergy, and enhanced killing by cycle-active drugs. 50 These observations led Goodman et al. 50 to propose that 'the ability to induce B-CLL cells into cell-cycle entry and/or into activation-induced apoptosis or into phases of the cell cycle sensitive to cytotoxic therapy opens up new perspectives for the development of potentially curative strategies for this chronic leukemia'.
CLL cells activated by the imidazoquinoline, S28690, were also found to be killed more easily by CTLs in vitro. 32 This increase in sensitivity to cell death was caused by other imidazoquinolines and extended beyond CTLs to include some chemotherapeutic agents. Whereas acute treatment with S26890 conferred protection from vincristine, CLL cells that had been exposed to S28690 cells for at least 48 h were killed by otherwise non-toxic doses of this microtubule inhibitor (manuscript submitted). As with CpG oligonucleotides, it is not clear why CLL cells that have been activated by imidazoquinolines become more sensitive to CTLs or cytotoxic drugs.
Clinical use of TLR agonists in CLL
Although the mechanisms whereby CLL cells exposed to TLR-7 or TLR-9 agonists are sensitized to killing have not yet been elucidated, it is possible that they may be exploited to enhance the susceptibility of tumor cells to conventional chemotherapy or to tumor-reactive CTLs that have been activated by a cancer vaccine. At present, the use of TLR agonists in CLL patients is mainly at the phase I clinical trial level, rather than in combination with other agents (Table 1) .
CpG oligonucleotides have been studied in lymphoma patients. There are at least three classes of CpG molecules that differ on the basis of their immunological effects and structure. CpG-A sequences include both phosphodiester and phosporothioate nucleotides, whereas CpG-B sequences have only a phosphorothioate backbone. The CpG-B oligonucleotide, CpG 7909, has been evaluated as a single agent given weekly for three injections and found to be well-tolerated with typical side effects of immunologically active agents, including fever and fatigue. 67 It is possible that observations in lymphoma patients may not apply directly to CLL patients (because the number of tumor cells in the target population may be larger), and a trial of CpG 7909 in CLL patients is ongoing through the University of Iowa and Mayo Clinic Lymphoma Spore (Table 1) . 68 Loxoribine has been evaluated in solid tumor patients and found to be safe and produce modest immunologic effects. 69 Despite the synergy with chemotherapeutic agents in vitro (described above 50, 65, 66 ), studies of loxoribine in CLL patients have not been reported.
The effects of the imidazoquinoline, S28690, on CLL cells in vitro 32 suggested that TLR-7 activation might have clinical activity in CLL. Accordingly, topical imiquimod (another imidazoquinoline licensed for the treatment of genital warts and certain skin cancers 16 ) was used to treat a patient with skin involvement by CLL cells and found to clear cutaneous leukemia cells over a period of several weeks. 35 Minimal systemic activity was noted, but the strong local activity suggested that intravenous administration of imidazoquinolines might be useful for treating CLL. Accordingly, a phase I dose-escalation trial of the TLR-7-specific imidazoquinoline, 852A, 70 is ongoing at the Toronto-Sunnybrook Regional Cancer Center, based on the results of a previous phase-I study in solid tumor patients, which suggested a maximum tolerated dose of 1.2 mg/m 2 . 71 Other ongoing trials of 852A and CpG 7909 include CLL patients but do not specifically target CLL (Table 1) . 
Summary and future directions
Use of TLR agonists in the management of CLL is supported by a number of anecdotal and laboratory observations, and preliminary observations from ongoing clinical trials suggest that these agents will have acceptable toxicity in CLL patients. Already it seems clear that TLR agonists will not be highly active as single agents but that their potential importance in CLL is through their ability to sensitize tumor cells to cytotoxic agents, including CTLs. Accordingly, the future of both CpG oligonucleotides and imidazoquinolines probably lies in combination with radiotherapies, existing chemotherapeutic regimens (including alkylating agents and fludarabine), or targeted agents such as denileukin diftitox (ONTAK), 72 rituximab and alemtuzumab. These agents could also be combined with cytokines, such as IL-2, to increase further the susceptibility of CLL cells to cytotoxic agents that are especially active against cycling cells.
50
CpG oligonucleotides and imidazoquinolines could also improve the efficacy of immunotherapies for CLL. The ability of imidazoquinolines, coupled with PKC agonists and IL-2, to rapidly and easily turn CLL cells into DC-like cells, regardless of their underlying cytogenetic abnormalities, 41 offers a potentially effective strategy for making autologous vaccines to prevent disease progression in untreated patients, or prolonged responses after initial treatment. 54 Depending on clinical toxicity, this combination could potentially be administered directly to patients to turn CLL cells into endogenous vaccines in vivo. Infusions of TLR-7 agonists could then be given to enhance the susceptibility of target tumor cells to the lytic effects of the vaccine-activated tumor-reactive T cells. 3 Agonists of other TLRs, that are expressed on a broader range of immune cells than TLR-7 and TLR-9, may be incorporated into these strategies to further activate the immune system and increase tumor clearance. 73 Many practical questions remain unanswered at the moment, including the appropriate dose, schedule, route and duration of administration. For example, the intravenous route of administration may cause sub-populations of splenic DCs to make indoleamine 2,3-dioxygenase, which degrades tryptophan required by effector T cells, and may downregulate anti-tumor immunity, and even promote tumor growth. 74, 75 Accordingly, it may be necessary to give TLR agonists through the intradermal or subcutaneous routes, as lymph nodes lack this DC subpopulation. 75 In addition, some pre-clinical studies suggest that TLR agonists may inhibit the effects of chemotherapy, when given at the same time. 76 This problem may be obviated by giving the TLR agonists before or after the chemotherapeutic agents. The relevance to clinical outcomes of the effects of cytogenetic abnormalities 56 and CD38 expression 32 on the quality of TLR signaling in CLL cells in vitro (as well as the mechanisms of these effects) remains to be determined. Similarly, the effects of other biological markers of disease progression in CLL, such as the microRNA signature, 77 expression of the extracellular nucleotide receptor, P2X7R 78 and expression of ZAP-70, 55 on TLR-7 and TLR-9 signaling in CLL cells are topics for further investigation.
In summary, there is intriguing early data about the effects of TLR agonists on CLL cells in vitro. However, much work remains to be carried out in order to determine whether these agents will have a role in the management of CLL.
